$16.7 B

BMRN Mkt cap, 04-Dec-2018

$391.7 M

BioMarin Pharmaceutical Revenue Q3, 2018
BioMarin Pharmaceutical Gross profit (Q3, 2018)312.8 M
BioMarin Pharmaceutical Gross profit margin (Q3, 2018), %79.9%
BioMarin Pharmaceutical Net income (Q3, 2018)-12.6 M
BioMarin Pharmaceutical EBIT (Q3, 2018)-15.7 M
BioMarin Pharmaceutical Cash, 30-Sep-2018882.2 M

BioMarin Pharmaceutical Revenue

BioMarin Pharmaceutical revenue was $1.31 b in FY, 2017

Embed Graph

BioMarin Pharmaceutical Revenue Breakdown

Embed Graph

BioMarin Pharmaceutical revenue breakdown by geographic segment: 18.4% from Rest of the World , 13.3% from Latin America, 22.7% from Europe and 45.5% from United States

BioMarin Pharmaceutical Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

548.5m751.0m889.9m1.1b1.3b

Revenue growth, %

37%18%26%

Cost of goods sold

95.7m129.8m152.0m209.6m241.8m

Gross profit

452.7m621.3m737.9m907.2m1.1b

Gross profit Margin, %

83%83%83%81%82%

R&D expense

661.9b610.8m

General and administrative expense

476.6b554.3m

Operating expense total

1.1t1.3b

EBIT

(156.0m)(92.9m)(110.7m)(803.4m)(14.7m)

EBIT margin, %

(28%)(12%)(12%)(72%)(1%)

Interest expense

10.4m36.6m38.2m39.5m42.7m

Interest income

3.1m5.9m4.5m7.5b14.9m

Pre tax profit

(176.5m)(124.9m)(154.7m)(831.0m)(35.9m)

Income tax expense

(150.0k)9.1m17.1m(200.8m)81.2m

Net Income

(176.4m)(134.0m)(171.8m)(630.2m)(117.0m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

136.9m151.6m191.8m176.8m203.3m250.5m208.9m236.7m300.0m279.9m303.7m317.4m334.1m373.4m372.8m391.7m

Cost of goods sold

28.1m22.8m31.2m29.9m32.8m39.9m36.7m43.1m51.6m50.7m50.0m56.3m59.5m82.3m79.0m78.9m

Gross profit

108.8m128.7m160.6m146.9m170.5m210.6m172.2m193.6m248.4m229.2m253.7m261.1m274.7m291.1m293.8m312.8m

Gross profit Margin, %

80%85%84%83%84%84%82%82%83%82%84%82%82%78%79%80%

R&D expense

88.1m86.2m107.7m125.7m142.1m157.9m158.7m158.8m167.0m160.8m145.0m143.0m154.1m183.9m175.6m161.4m

General and administrative expense

61.8m60.1m68.1m74.6m92.8m101.5m94.0m105.3m110.0m118.8m120.0m143.5m130.5m138.3m153.3m148.6m

Operating expense total

187.6m178.0m210.7m165.6m269.1m314.8m290.8m317.7m873.0m340.0m324.0m356.3m347.9m417.8m398.1m407.4m

EBIT

(50.7m)(26.5m)(18.9m)11.2m(65.9m)(64.2m)(81.9m)(80.9m)(573.0m)(60.1m)(20.2m)(38.8m)(13.7m)(44.4m)(25.3m)(15.7m)

EBIT margin, %

(37%)(17%)(10%)6%(32%)(26%)(39%)(34%)(191%)(21%)(7%)(12%)(4%)(12%)(7%)(4%)

Interest expense

526.0k9.1m9.2m9.1m9.5m10.0m9.4m9.8m9.9m10.0m10.1m10.0m10.9m11.6m12.2m12.1m

Interest income

574.0k1.1m1.7m1.4m683.0k1.0m1.3m1.6m1.4m1.6m3.1m3.0m4.0m5.2m5.6m6.3m

Pre tax profit

(52.3m)(34.6m)(27.7m)3.2m(74.7m)(82.5m)(90.4m)(89.1m)(583.0m)(66.8m)(24.3m)(45.5m)(20.6m)(50.8m)(29.2m)(19.4m)

Income tax expense

704.0k3.5m5.8m(4.2m)(7.2m)(555.0k)483.0k(24.0m)(6.7m)(12.4m)(6.8m)

Net Income

(53.0m)(38.1m)(33.5m)7.4m(67.5m)(82.0m)(90.9m)(85.1m)(424.0m)(42.8m)(16.3m)(36.8m)(12.5m)(44.1m)(16.8m)(12.6m)

BioMarin Pharmaceutical Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

568.8m875.5m397.0m408.3m598.0m

Accounts Receivable

117.8m144.5m165.0m215.3m261.4m

Inventories

162.6m199.5m271.7m355.1m475.8m

Current Assets

1.1b1.4b1.1b1.4b2.2b

PP&E

319.3m523.5m704.2m798.8m896.7m

Goodwill

54.3m54.3m197.0m197.0m197.0m

Total Assets

2.2b2.5b3.7b4.0b4.6b

Accounts Payable

183.3m392.5m370.5m401.9m

Current Liabilities

183.3m235.7m445.5m439.3m816.5m

Total Liabilities

908.2m1.3b1.3b1.8b

Additional Paid-in Capital

2.1b2.4b3.4b4.3b4.5b

Retained Earnings

(715.8m)(849.8m)(1.0b)(1.5b)(1.6b)

Total Equity

1.3b1.5b2.4b2.8b2.8b

Financial Leverage

1.7 x1.6 x1.6 x1.5 x1.6 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

181.6m639.8m584.7m398.0m900.6m440.7m376.3m270.5m306.0m707.3m348.2m354.9m431.4m474.0m427.4m882.2m

Accounts Receivable

124.7m110.5m122.3m121.4m175.7m186.1m148.9m180.8m214.2m215.9m230.3m238.3m251.9m318.4m363.6m384.3m

Inventories

148.7m176.9m193.5m204.4m222.8m237.5m262.1m297.0m326.6m347.4m384.1m429.8m457.4m468.2m473.4m508.5m

Current Assets

713.5m1.2b1.2b1.1b1.5b1.2b1.2b992.8m1.1b1.7b1.4b1.5b2.1b2.2b2.3b2.4b

PP&E

285.7m437.1m469.9m486.7m538.1m568.1m604.5m716.9m724.5m729.8m824.0m851.1m878.6m895.4m900.5m924.0m

Goodwill

54.3m54.3m54.3m54.3m202.4m202.4m202.4m197.0m197.0m197.0m197.0m197.0m197.0m197.0m197.0m197.0m

Total Assets

1.6b2.3b2.3b2.4b3.7b3.6b3.6b3.7b3.1b3.8b3.9b4.0b4.6b4.6b4.6b4.7b

Accounts Payable

167.6m156.0m166.7m206.6m230.2m256.3m296.2m290.6m292.3m306.1m272.4m319.2m364.9m346.5m358.7m378.2m

Current Liabilities

167.6m156.0m166.7m206.6m305.5m347.7m390.5m388.0m364.6m377.3m340.2m374.3m417.5m773.5m805.0m838.7m

Total Liabilities

344.0m880.6m883.7m932.0m1.2b1.3b1.3b1.4b1.2b1.2b1.2b1.2b1.8b1.8b1.7b1.8b

Additional Paid-in Capital

1.9b2.2b2.2b2.3b3.3b3.3b3.4b3.4b3.5b4.2b4.3b4.4b4.4b4.5b4.6b4.6b

Retained Earnings

(653.8m)(753.9m)(787.4m)(780.0m)(917.3m)(999.3m)(1.1b)(1.1b)(1.5b)(1.6b)(1.5b)(1.6b)(1.6b)(1.7b)(1.7b)(1.7b)

Total Equity

1.3b1.5b1.5b1.5b2.4b2.3b2.3b1.9b2.6b2.8b2.8b2.8b2.8b2.9b2.9b

Financial Leverage

1.3 x1.6 x1.6 x1.6 x1.5 x1.6 x1.6 x1.6 x1.5 x1.4 x1.4 x1.6 x1.6 x1.6 x1.6 x

BioMarin Pharmaceutical Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(176.4m)(134.0m)(171.8m)(630.2m)(117.0m)

Depreciation and Amortization

47.3m56.7m47.2m96.9m87.9m

Accounts Receivable

(8.8m)(27.0m)(16.4m)(51.5m)(25.3m)

Inventories

(33.9m)(37.0m)(51.0m)(64.5m)(96.9m)

Accounts Payable

20.4m90.3m(53.2m)45.5m

Cash From Operating Activities

(59.6m)(73.5m)(221.7m)(227.8m)(8.8m)

Purchases of PP&E

(65.1m)(118.8m)(227.7m)(148.4m)(199.2m)

Cash From Investing Activities

(298.8m)194.6m(1.2b)(484.0m)(305.5m)

Cash From Financing Activities

746.7m185.7m927.9m727.1m507.1m

Income Taxes Paid

14.9m35.0m16.1m95.9m23.9m

BioMarin Pharmaceutical Ratios

USDY, 2018

Financial Leverage

1.6 x
Report incorrect company information

BioMarin Pharmaceutical Operating Metrics

FY, 2016

Patent Applications

426

Patents Issued

1.17 k

Phase 1/2 Trials Products

2

Phase III Trials Products

2
Report incorrect company information

BioMarin Pharmaceutical Employee Rating

3.4262 votes
Culture & Values
3.8
Work/Life Balance
3.3
Senior Management
3.1
Salary & Benefits
3.8
Career Opportunities
3.5
Source